Promising therapeutic strategies targeting NLRP3 include small molecule inhibitors such as MCC950, which reduce systemic inflammation and improve glycemic control, and dietary interventions, such as n-3 polyunsaturated fatty acids (PUFAs) like DHA, which block saturated fat-triggered NLRP3 activation and insulin resistance [63,69,71,131,132,133]. Here, NLRP3 is linked to Insulin resistance.